<DOC>
	<DOC>NCT00724360</DOC>
	<brief_summary>This is a multicenter open-label phase II trial of trastuzumab in patients with HER2 positive B-ALL in relapse, or with refractory disease. Herceptin is administered as a 4 mg/kg intravenous loading dose followed by 2 mg/kg weekly for at least 2 months and/or till progression. Response and HER2 expression are assessed each month by bone marrow aspirate.</brief_summary>
	<brief_title>Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>age &gt; 18 years BALL in relapse refractory BALLperformance status of 02 on the Eastern Cooperative Oncology Group scale adequate hepatic and renal functions (AST or ALT &lt;= 5 times the upper limit of normal creatinine &lt; 2 times the upper limit of normal) &gt; 20% blasts in bone marrow, &gt; 30% of bone marrow blast population HER2 positive as assessed by immunophenotyping Previous treatment by trastuzumab FEVG &lt; 50%</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>relapsed/refractory</keyword>
	<keyword>HER2</keyword>
	<keyword>positive</keyword>
	<keyword>B-ALL</keyword>
	<keyword>trastuzumab</keyword>
</DOC>